Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Carisma Therapeutics ( (CARM) ) has issued an announcement.
Carisma Therapeutics Inc. has entered into a master services agreement with Danforth Global, Inc. and Danforth Advisors, LLC to receive finance and accounting services from Natalie McAndrew, who will serve as the interim Vice President of Finance and principal financial officer. This strategic appointment is expected to bolster the company’s financial management capabilities, enhancing its operational efficiency and potentially impacting its industry standing positively.
More about Carisma Therapeutics
YTD Price Performance: -86.38%
Average Trading Volume: 222,366
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $16.66M
See more insights into CARM stock on TipRanks’ Stock Analysis page.